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ABSTRACT 
 
Activation of the innate immune system in obesity is a risk factor for the 
development of type 2 diabetes. The aim of the current study was to investigate 
the notion that increased numbers of macrophages exist in the islets of type 2 
diabetes patients, and that this may be explained by a dysregulation of islet-
derived inflammatory factors. Increased islet-associated immune cells were 
observed in human type 2 diabetic patients, high fat (HF) fed C57BL/6 mice, the 
GK rat, and the db/db mouse. When cultured islets were exposed to a type 2 
diabetic milieu or when islets were isolated from HF fed mice, increased islet-
derived inflammatory factors were produced and released, including IL-6, IL-8, 
chemokine KC, G-CSF, and MIP-1α. The specificity of this response was 
investigated by direct comparison to non-islet pancreatic tissue and β-cell lines, 
and was not mimicked by the induction of islet cell death. Further, this 
inflammatory response was found to be biologically functional, since conditioned 
medium from human islets exposed to a type 2 diabetic milieu could induce 
increased migration of monocytes and neutrophils. This migration was blocked 
by IL-8 neutralization, and IL-8 was localized to the human pancreatic α-cell. 
Therefore, islet-derived inflammatory factors are regulated by a type 2 diabetic 
milieu and may contribute to the macrophage infiltration of pancreatic islets we 
observe in type 2 diabetes. 
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INTRODUCTION 
 
Activation of the innate immune 
system has long been reported in 
obesity, insulin resistance, and type 2 
diabetics, characterized by increased 
circulating levels of acute-phase 
proteins, and cytokines and 
chemokines (1-5). However, the 
notion that excess circulating nutrients 
may stimulate the β-cell to produce 
chemokines remains unexplored, and 
immune cell infiltration has not been 
shown in islets of type 2 diabetic 
patients. 
 One of the most classical 
chemotactic agents in immunology is 
the CXC family chemokine, IL-8 
(CXCL8)(6). IL-8 is produced by 
leukocytes, fibroblasts, endothelial 
and epithelial cells, and is commonly 
associated with infections, graft 
rejection, allergy, asthma, cancer, and 
atherosclerosis. In addition to its 
effect on neutrophils, the chemotactic 
effect of IL-8 is also important in 
mediating monocyte migration (7-9). 
The rodent does not express IL-8. 
Instead, the rodent functional 
homologue of IL-8 is thought to be 
chemokine KC (CXCL1, or Gro-α in 
the rat), which has also been reported 
to induce granulocyte and monocyte 
migration (9). Chemokine KC is 
thought to be an ortholog of human 
CXCL1. Circulating levels of IL-8 are 
elevated in type 2 diabetics (10; 11), 
where it has been implicated in 
systemic insulin resistance and 
atherosclerosis (12; 13).   
 Thus, we hypothesized that 
pancreatic islets in type 2 diabetes 
are characterized by increased 
macrophage infiltration, and that a 
type 2 diabetic milieu could promote 
chemokine production in pancreatic 
islets. In investigating this premise, 
we found increased numbers of 
macrophages associated with islets of 
type 2 diabetes patients and animal 
models of this disease, and have 
identified various nutrient-regulated 
islet-derived inflammatory factors 
(including IL-6, IL-8, chemokine KC, 
G-CSF, and MIP-1α). Given these 
factors, we have identified IL-8 to be 
an integral chemokine mediating 
monocyte and neutrophil chemotaxis 
by conditioned medium from human 
islets exposed to a type 2 diabetic 
milieu. Finally, we have localized islet-
derived IL-8 to the human pancreatic 
α-cell.    
 
RESEARCH DESIGN AND 
METHODS
 
Tissue samples and 
immunohistochemistry.  For specific 
human sample information, see Table 
1. Patients with pancreatitis, 
lymphoma, systemic infection, and on 
immunosuppressive therapy were 
excluded from analysis. Pancreata 
were procured for histology and islet 
isolation according to regulations and 
good practice rules applied at that 
time in Switzerland. Briefly, consent 
was considered obtained if the 
potential donor carried an official 
organ Swisstransplant (Swiss national 
organ sharing agency) donor card, on 
which individual reservations about 
procurement of specific organs or 
tissues are explicitly mentioned. For 
brain-dead potential donors not 
carrying an organ donor card, consent 
was obtained orally from the closest 
relatives and specifically mentioning 
the use of the pancreas for islet 
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isolation or histology. Use of 
pancreatic tissue was approved by the 
cantonal ethical committee, number 
StV 29-2006.  
 
Immune cell immunohistochemistry:  
Human tissue samples were fixed in 
formalin, 4 µm sections were cut, and 
immunohistochemistry was performed 
on an automated stainer (Ventana 
benchmark, Tucson, AZ, USA) after 
protease 1 (Ventana) pretreatment. 
Sections were incubated with an anti-
CD68, anti-CD163, or anti-HLA 2 
antibody (Ab; mouse anti-human 
CD68, clone PG-M1, 1:50, Dako, 
Glostrup, Denmark; mouse anti-
human CD163, clone 163C01/10D6, 
1:100, NeoMarkers/Lab Vision 
Corporation, Newmarket Suffolk, UK; 
mouse anti-human HLA Class 2 
(DP+DQ+DR), clone IQU9, 1:50, 
Novocastra Laboratories Ltd, 
Newcastle, UK), followed by a 
biotinylated secondary Ab (Ventana). 
Staining was visualized with the I-view 
DAB detection kit (Ventana). Sections 
were co-stained with an anti-insulin Ab 
(polyclonal guinea pig anti-insulin, 
1:500, Dako) followed by a prediluted 
secondary Ab, and chromogenically 
detected via the Ventana alkaline 
phosphatase (AP) Fast Red Kit. 
Counterstaining was done with 
hematoxylin. Islet associated 
granulocytes were stained for by H&E 
morphology and using an anti-human 
myeloperoxidase Ab (Rabbit 
polyclonal, 1:15000; Dako). The CD68 
Ab was used as previously shown 
(14), and controlled by mouse IgG Ab 
staining. For TUNEL detection, 
sections were permeabilized with 
proteinase K (20 µg/mL) and 
endogenous peroxidases were 
blocked with 3 % H2O2. Sections 
were incubated with working strength 
TdT enzyme (ApopTag kit S7100; 
Millipore; Switzerland). After rinsing 
sections with a stop-buffer the slides 
were covered by anti-digoxigenin 
peroxidase conjugate, rinsed and then 
incubated with rabbit anti-sheep HRP 
antibody (1:80). Detection was 
performed with DAB (Ventana) and 
haematoxylin was used for 
counterstaining.  
Mouse pancreatic cryosections 
were incubated with an anti-Cd11b 
primary Ab (BD Pharmingen, Basel, 
Switzerland; 1:167), isotype rat IgG2B 
(Serotec, Düsseldorf, Germany), anti-
insulin Ab (Dako), and Dapi to identify 
nuclei. This Cd11b Ab has been 
published by us previously (15); 
mouse spleen served as a positive 
tissue control. Primary Abs were 
visualized using Strep-Cy3 secondary 
and FITC secondary antibodies 
respectively (Jackson 
Immunoresearch, Newmarket, UK), 
and pictures captured on an Axioplan2 
imaging system (Zeiss, Feldbach, 
Switzerland). Additionally, some 
sections were visualized with 3-amino-
9-ethylcarbazole (AEC) substrate and 
counterstained with hematoxylin.  
Wistar and GK rat cryosections 
were incubated with mouse anti-rat-IA 
(MHC II; Serotec; 1:300) and ED1 
mouse anti-rat CD68 (Serotec; 1:100), 
followed by incubation with goat anti-
mouse secondary (Caltag, Cergy, 
France) and visualized with AEC 
substrate. For each series of pancreas 
sections, one slide was stained only 
with the second antibody as a control 
for endogenous peroxidase activity 
and non-specific antibody binding as 
previously published (16). 
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IL-8 immunohistochemistry:  
Pancreatic resection samples (3 
control and 4 type 2 diabetic patients) 
and sorted human non-beta cells 
plated on ECM were analyzed for IL-8 
expression. Human glioblastoma 
sections were used as a positive 
control for IL-8 staining as previously 
shown (17). Sections and sorted non-
beta cells were incubated with a rabbit 
anti-IL-8 primary Ab (Abcam ab16223, 
Cambridge, UK; 1:50), or isotype 
control (rabbit IgG, R&D Systems, 
Abingdon, UK). Antibody specificity 
was tested using recombinant IL-8 
protein (Abcam ab6931) to block 
binding. IL-8 was visualized using 
AEC, Cy-3 anti-rabbit, or Alexa 
Fluor®488 donkey anti-rabbit IgG 
secondary (Molecular probes, 
Eugene, OR, USA). Sections were 
further incubated with guinea pig anti-
insulin or guinea pig anti-glucagon 
(Dako, 1:50) followed by a FITC 
secondary. Non-beta cells were 
incubated with the above glucagon 
Ab, rhodamine-conjugated goat anti-
guinea pig (Jackson, Suffolk, UK) 
secondary, and nuclei were labeled 
with Hoechst 33342 (Sigma, Buchs, 
Switzerland). Further, the same IL-8 
Ab was used in Western blotting of 
human islet samples. Recombinant IL-
8 (R&D Systems) was used as a 
positive control for Western blotting.  
 
Islet immune cell scoring:  An 
average of 43 ± 17 islets from 
nondiabetic (n=7) and 35 ± 12 islets 
from diabetic (n=9) pancreatic 
sections were blindly scored for 
CD68+ cells around the periphery 
and/or within islets by two 
investigators (A.P and X.G). CD163 
and HLA-2 was used to confirm 
macrophage identity in resection 
samples. To evaluate TUNEL+ cells 
localized to CD68+ infiltrated islets, 
190 islets from 3 diabetic patients 
(resection samples) showing strong 
infiltration were evaluated in serial 
sections stained for TUNEL and 
CD68. Post-mortem interval time for 
autopsy samples ranged from 7-24h, 
and archive time for all samples 
ranged from 24-99 months. Pancreatic 
sections from the corpus and tail of 
the pancreas were examined.  
Islet-associated Cd11b positive 
cells were scored by a single 
investigator (J.A.E.) blinded to the 
conditions. Only Cd11b positive cells 
around the periphery of pancreatic 
islets or within islets were scored. For 
each animal in the study (n=3-7), 4 to 
8 pancreatic sections cut at 60-80 µm 
intervals were scored. Data are 
expressed as Cd11b positive 
cells/islet, where “islet” refers to a 
cross-sectionally detected islet 
defined by size (small islet: 1-5 cross 
sectional cells, medium islet: 5-20 
cross sectional cells; large islet: 20-50 
cross sectional cells). A total of 100 to 
200 islets per treatment group were 
scored. Islet area was measured by 
assessing the area of insulin 
immunopositive cells, traced manually 
and computed using analySISTM 3.1 
software (Soft Imaging System GmbH, 
Münster, Germany). TUNEL positive 
cells were analyzed in 20.6 ± 0.4 islets 
and 25.0 ± 5.2 islets/animal in 8 and 
16 week chow and HF fed animals (8 
week; n=5 and 16 week: n=6; In Situ 
Cell Detection Kit, AP, Roche, Basel, 
Switzerland). Islet associated CD68+ 
and MHC II+ cells in Wistar and GK 
rats were scored in islets from 6 to 9 
different animals. 
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Animals and glucose tolerance 
testing. Male C57BL/6J mice (Harlan, 
Horst, Netherlands) were used for all 
mouse islet experiments. In some 
cases, animals were fed a 
hypercaloric diet (high fat; HF) 
manufactured by Research Diets 
(New Brunswick, NJ, USA). The HF 
diet contained 58, 26 and 16% 
calories from fat, carbohydrate and 
protein, respectively, and a total of 5.6 
kcal/g, whereas the control diet was 
manufactured by Provimi Kliba AG 
(Kaiseraugst, Switzerland) and 
contained 29, 39 and 32% calories 
from fat, carbohydrate and protein, 
respectively, and a total of 2.8 kcal/g. 
For assessment of Cd11b+ cells 
around islets, animals were started on 
HF diet at age 3-4 weeks, for ex vivo 
determination of islet cytokines and 
chemokines animals were started on 
HF diet at age 8 weeks. For glucose 
tolerance testing, mice were injected 
i.p. with 2 mg/g body weight glucose 
(IPGTT) and blood glucose 
concentration was measured with a 
Freestyle™ glucometer (Abbott, Baar, 
Switzerland).  
Characteristics of the GK rat 
maintained in the colony at the Paris 7 
University have been described 
previously (18). This animal model 
was developed by inbreeding Wistar 
rats with mild hyperglycemia. Male GK 
rats are normoglycemic prior to 
weaning (1 month), with 
hyperglycemia, hypercholesterolemia 
and hypertriglyceridemia developing 
shortly after weaning, followed by 
insulin resistance at 2 months. Male 
db/db and db/+ littermate controls 
were purchased from Jackson (Bar 
Harbour, ME, USA). Guidelines for the 
use and care of laboratory animals at 
the University of Zurich were followed. 
Islet isolation, α-cell purification, 
and cell culture. Human islets were 
isolated from pancreata of 14 organ 
donors at the University of Geneva 
Medical Center and the University of 
Illinois at Chicago. All human islet 
preparations were stained with 
dithizone (>80% purity of islets) and 
insulin (40-50% β-cells/islet) to 
monitor purity, and were hand-picked 
and plated by a single investigator 
(J.A.E.) to maintain consistency. 
Human non-beta cells were isolated 
using a method adapted from (19) and 
(20) (Parnaud et al, submitted). 
Mouse islets and non-endocrine 
pancreatic tissue were isolated from 
C57BL/6J mice by collagenase 
digestion and hand-picking of islets. 
After collagenase digestion, non-
endocrine tissue was recovered as a 
pellet and islets were removed by 
handpicking as reported (21). Human 
islets were cultured in CMRL 1066 
medium containing 5.5 mM glucose, 
100 U/mL penicillin, 100 ug/ml 
streptomycin, and 10 % FCS 
(Invitrogen Ltd., Basel, Switzerland). 
Mouse islets and non-endocrine tissue 
were cultured in RPMI 1640 medium 
containing 11 mM glucose, 100 U/ml 
penicillin, 100 µg/ml streptomycin, 40 
µg/ml Gentamycin and 10% FCS 
(hereafter referred to as islet media). 
Islets were cultured on extracellular 
matrix (ECM)-coated plates (at 20 
islets/plate) derived from bovine 
corneal endothelial cells (Novamed, 
Jerusalem, Israel) as previously 
described (22). In experiments using 
ECM dishes, islets and non-endocrine 
tissue were left 48 h in islet media to 
adhere and spread before initiation of 
experiments. INS-1 cells were kindly 
donated by Dr. S.A. Hinke (Belgium) 
and MIN-6 cells were donated by Dr. 
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P. Halban (Geneva), and cultured as 
previously described (23). MIN-6 and 
INS-1 cells were seeded at 5 x 105 
cells/well and control conditions 
included 25 mM and 11 mM glucose 
media respectively. 
In some experiments islets 
were treated with 33 mM glucose 
and/or 0.5 mM palmitate (Sigma). 
Palmitic acid was dissolved at 10 
mmol/l in RPMI-1640 medium 
containing 11% fatty acid—free BSA 
(Sigma) under an N2-atmosphere, 
shaken overnight at 55°C, sonicated 
15 min, and filtrated under sterile 
conditions.  For control incubations, 
11% BSA was prepared, as described 
above. Before use, the effective free 
fatty acid concentrations were 
controlled with a commercially 
available kit (Wako, Neuss, Germany). 
In some experiments 500 nM 
staurosporine or 0.1 and 1 mM 
streptozotocin were added to mouse 
islets for 48h to induce cell death. Cell 
death was confirmed by TUNEL 
(Roche). 
 
Insulin secretion. For acute insulin 
release in response to glucose, islets 
were washed and incubated in Krebs-
Ringer buffer (KRB) containing 2.8 
mM or 16.7 mM glucose and 0.5% 
BSA for 1 h. Islet insulin was extracted 
with 0.18 M HCl in 70% ethanol for 
determination of insulin content. 
Secreted insulin and insulin content 
was assayed by RIA (CIS 
Biointernational, Gif-sur-Yvette, 
France).  
 
Cytokines and chemokines. 
Conditioned media and serum 
cytokines and chemokines were 
assayed using human, mouse, and rat 
Luminex™ kits. In some islet 
experiments cytokine/chemokine 
release was normalised to total islet 
protein, extracted using lysis buffer 
and measured using the BCA assay 
(Pierce, Rockford, IL, USA).  
 
RNA extraction and real-time PCR. 
Total mouse islet RNA was extracted 
as described (22) and reverse 
transcribed using random hexamers. 
Commercially available mouse 
primers to 18S rRNA, IL-6, chemokine 
KC, G-CSF, and MIP-1α were 
purchased and assayed according to 
the manufacturer’s protocol using the 
ABI 7000 system (Applied 
Biosystems, Foster City, CA, USA). 
Changes in mRNA expression were 
calculated using difference of CT 
values.      
 
Migration assay. To evaluate 
monocyte and neutrophil migration 
peripheral blood mononuclear cells 
(PBMCs) and granulocytes were 
isolated from a single healthy male 
donor using Histopaque®, as per the 
manufacturer’s protocol (Sigma). 
Migration was tested using Transwell 
membranes by loading a mix of  
 
1 x 106 PBMCs and 5 x 105 
granulocytes into the upper chamber, 
and human islet medium or human 
islet supernatant into the lower 
chamber. Experiments were carried 
out in X-Vivo 15 medium (Cambrex, 
Verviers, Belgium), where islet culture 
medium and islet supernatants were 
diluted 10x. Human islet supernatants 
treated without (untreated) and with 
33 mM glucose and 0.5 mM palmitate 
(treated) for 48h were used. Migration 
was allowed to proceed for 4 h at 37 
oC before evaluation of total cells 
migrated by flow cytometry (FACScan, 
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BD Biosciences). Identification of 
migrated monocytes and neutrophils 
was achieved using FITC-conjugated 
anti-CD14 and CD15 monoclonal 
antibodies respectively (BD 
Biosciences). Appropriate isotype 
controls were used to ensure Ab 
specificity. IL-8 was neutralized by 
addition of an IL-8 antibody or normal 
goat isotype control (30 µg/mL; R&D 
Systems) to the lower chamber and 
preincubation for 30 minutes with 
conditioned media before the addition 
of cells to the upper chamber. In 
control experiments, the IL-8 antibody 
was found to block recombinant IL-8 
induced migration. 
 
IL-8 electron microscopy. Islets from 
4 separate human islet isolations were 
fixed by immersion in a fixation 
solution containing 2,5% 
paraformaldehyde, 0,1% 
glutaraldehyde and 0,01% picric acid 
for 4 h. Thereafter, specimens were 
dehydrated and embedded routinely in 
LR White (Polysciences, Warrington, 
USA). Ultrathin sections were cut at 
90 nm and transferred onto nickel 
grids (mesh size 100). Sections were 
incubated with a mouse glucagon 
antiserum (G-2654, Sigma, St. Louis, 
USA; 1:100) followed by biotinylated 
anti-mouse IgG (Amersham 
International, Dübendorf, Switzerland) 
and a streptavidin-gold-5 nm complex 
(Amersham). IL-8 was visualized 
using rabbit IL-8 antiserum (Abcam; 
1:50) followed by biotinylated goat 
anti-rabbit IgG (Bioscience, 
Emmenbrücke, Switzerland) and a 
streptavidin-gold-15 nm complex 
(Amersham). Sections were examined 
with a Philips CM 100 electron 
microscope and digitally analysed with 
Gatan Bioscan Digital Micrograph 
(Gatan, Pleasanton, CA, USA). 
 
Statistics. Data are expressed as 
means ± S.E. with the number of 
individual experiments presented in 
the figure legends. All data were 
tested for normality and analyzed 
using the nonlinear regression 
analysis program PRISM (GraphPad, 
CA, USA). Significance was tested 
using the Student's t-test and analysis 
of variance (ANOVA) with 
Bonferonni’s or Dunnett's post hoc test 
for multiple comparison analysis. 
Significance was set at p < 0.05.  
 
RESULTS 
 
Increased number of pancreatic-
islet associated macrophages in 
type 2 diabetes.  We investigated 
whether type 2 diabetic islets display 
immune cell infiltration. With respect 
to human samples, we observed 
increased numbers of islet-associated 
macrophages (based on CD68, 
CD163, and HLA-2 immunolabeling; 
CD163 and HLA-2 not shown) in 
human type 2 diabetic tissue from 
both autopsy and resection samples 
(Table 1 and Figure 1A-B). Islets with 
increased numbers of macrophages 
(>3 CD68+ cells/islet) were observed 
more frequently in type 2 diabetic 
samples compared to non-diabetic 
controls (Figure 1A; maximum of 19 
CD68+ cells/islet in type 2 diabetic 
samples). In contrast to islets of 
control patients with exclusive 
perivascular location of CD68+ 
macrophages, the affected islets 
showed intra-islet invasion (Figure 
1B). Type 2 diabetic islets 
characterized by increased CD68+ 
cells did not display increased 
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TUNEL+ cells and we never observed 
macrophages in the vicinity of 
apoptotic β-cells (Figure 1B). 
Numbers of TUNEL+ cells were 0.023 
± 0.011 vs. 0.046 ± 0.004 TUNEL+ 
cells/islet for non-diabetic (n=4) vs. 
diabetic (n=3) resection samples 
analyzed respectively. Numbers of 
CD68+ cells/islet did not correlate with 
post-mortem interval of autopsy 
samples (r2=0.15, p=0.34, n=8), or 
tissue archive time (r2=0.00066, 
p=0.93, n=15). Cases with intra-islet 
invasion were associated with 
decreased insulin immuno-reactivity, 
and amyloid deposits. These 
macrophages were positive for HLA-2 
and CD163 (data not shown). We saw 
no differences in pancreatic islet or 
exocrine associated granulocytes or 
CD3 positive T-cells in diabetic vs. 
non-diabetic samples, while some 
CD3 T-cells were observed in the peri-
islet region of all samples.  
To investigate the onset of 
increased islet-associated immune 
cells, we fed C57BL/6J mice a normal 
chow or HF diet and evaluated islet-
associated CD11b+ cells (a marker for 
macrophages in addition to dendritic 
and other myeloid cell lineages) after 
4, 8, and 16 weeks. After 8 weeks of 
HF feeding mice displayed glucose 
intolerance and remained so until the 
experiment was terminated at 16 
weeks (Figure 1C). In this model 
Cd11b+ cells were observed mostly at 
the periphery of islets (Figure 1D); the 
spleen served as a positive control for 
Cd11b staining (Figure 1E). Already 
after 8 weeks of HF feeding, we 
detected a doubling in the number of 
islet-associated CD11b+ cells 
exclusively around large islets in HF 
fed animals vs. chow controls of the 
same age. At 16 weeks there was a 
trend towards increased CD11b+ cells 
around medium sized islets as well. 
Large islets with >3 CD11b+ cells 
were observed more frequently in HF 
sections compared to chow controls 
(10 ± 6 % (n=4) vs. 48 ± 15 % of total 
islets with >3 CD11b+ cells (n=5) in 8 
week chow and HF fed samples 
respectively; p<0.05). Islet area of 
those large islets evaluated at 8 
weeks was not significantly different in 
HF versus normal diet fed animals 
(28720 ± 8930, n=4 vs. 27440 ± 4210 
µm2; n=5). Thus, increased islet-
associated CD11b+ cells around large 
islets was not due to a difference in 
islet size between normal and HF fed 
animals, and was detected as an early 
event following HF feeding. Analysis 
of islets in 8 and 16 week chow, and 8 
week HF fed animals revealed no 
TUNEL positive cells. In 16 week HF 
fed animals, 0.031 TUNEL+ cells/islet 
(2 TUNEL+ cells/65 islets analyzed 
from n=3 animals with highest number 
of Cd11b+ cells/islet) were detected. 
The GK rat is a rodent model of 
spontaneous type 2 diabetes 
established by inbreeding Wistar rats 
selected from the upper limit of a 
normal distribution for glucose 
tolerance (18). We analyzed the 
presence of islet-associated 
macrophages in 1-month (weaning; 
normogylcemic) and 2-month old male 
Wistar and GK rats (one month after 
chronic mild hyperglycemia; fasting 
glycemia:  6.3 ± 0.2 vs. 11.3 ± 0.6 
mM, n=10 for Wistar and GK rats 
respectively; p<0.05) using 2 different 
antibodies, ED-1 (CD68) and anti-
MHC class 2. There was no difference 
in macrophages associated with islets 
at 1 month of age (not shown). While 
few macrophages were present 
around Wistar islets, GK islets were 
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characterized by pronounced 
macrophage infiltration at 2 months of 
age (Figure 2). The mean islet area 
analyzed for CD68+ and MHC-2+ 
cells was identical in both strains for 
these comparisons (Figure 2B and D). 
Finally, we investigated 8-9 week old 
db/db mice and littermates (glucose 
intolerance develops between 4-8 
weeks of age) for islet-associated 
Cd11b+ cells. Fasting glycemia was 
4.0 ± 0.2 vs. 8.3 ± 0.7 mM for db/+ 
and db/db mice respectively (n=10, 
p<0.05). Compared to db/+ 
littermates, db/db mouse islets were 
characterized by increased peri-islet 
CD11b+ cell infiltration (2.6 ± 1.7 % 
(n=4) vs. 24.8 ± 4.9 % of total islets 
with >3 CD11b+ cells (n=5; p<0.05); 
1.6 ± 0.1 vs. 2.4 ± 0.3 Cd11b+ 
cells/islet; p<0.05, n=5 for db/+ and 
db/db respectively). 
 
Human and mouse islets release 
increased amounts of cytokines 
and chemokines in response to a 
type 2 diabetic milieu.  We 
hypothesized that pancreatic islets 
secrete factors that may attract 
macrophages under pathological 
conditions. After screening human 
islet, mouse islet and cell line 
preparations we concentrated on the 
regulation of IL-6, IL-8, G-CSF, IP-10, 
MIP-1α, MCP-1, and chemokine KC in 
the rodent (all known to be elevated in 
type 2 diabetic and obese subjects (1; 
2; 24)). After 48 h of treatment with 33 
mM glucose, or 0.5 mM palmitate (in 
combination or separately), we 
evaluated glucose-stimulated insulin 
secretion to ensure β-cell dysfunction 
(Figure 3A, B). As seen in Figure 3 (C-
E), mouse and human islets released 
profoundly more IL-6, IL-8, chemokine 
KC and G-CSF in response to 
elevated glucose and palmitate in 
combination after 48 h of treatment, 
while palmitate alone stimulated only 
some of these factors. Note that 
rodents do not express IL-8, and 
chemokine KC is thought to be its 
functional homologue in rodents. 
Further, IP-10 showed a trend towards 
regulation in human islets, with no 
change in mouse islets (Figure 3F). 
MIP-1α release was also significantly 
increased in human islet preparations 
in response to a diabetic milieu 
(Figure 3G), but was undetectable in 
mouse islet supernatants (data not 
shown). Finally, MCP-1 remained 
unaffected in human islets (Figure 3H; 
undetectable in mouse islets). 
The specificity of this islet 
inflammatory response to elevated 
glucose and palmitate was tested by 
comparison of endocrine and non-
endocrine tissue, by analysis of β-cell 
lines, and by the induction of cell 
death. While gluco-lipotoxic stress 
increased IL-6, KC, and G-CSF 
release from islets, these factors were 
not significantly increased in an equal 
quantity of non-endocrine tissue 
(Figure 4A-D). Further, to support our 
claim that these factors are islet-cell 
derived, both MIN-6 cells and INS-1 
cells were found to respond to 
elevated glucose and palmitate by 
releasing increased amounts of 
chemokine KC, G-CSF and MIP-1α 
(Figure 4E-H). Finally, to rule out that 
an unspecific stimulation by the 
apoptotic/necrotic process induced by 
glucose and palmitate was 
responsible for the increase in 
cytokine/chemokine release, we 
tested the effect of 48 h staurosporine 
(500 nM), and 0.1 and 1 mM 
streptozotocin treatment on mouse 
islets. Islet cell death induced by 
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either agent did not increase 
cytokine/chemokine release (Figure 
4I-K).   
 To examine whether the 
nutrient effects on the above 
cytokine/chemokines are mediated at 
the transcriptional level, we isolated 
mouse islet RNA after 48 h treatment 
under gluco-lipotoxic conditions. In 
contrast to the response seen at the 
protein level, the IL-6 transcript was 
downregulated by a diabetic milieu, 
while KC and G-CSF paralleled their 
protein response. Further, mouse 
MIP-1α was also strongly upregulated 
at the mRNA level (Figure 5).  
 We also tested the hypothesis 
that chemokine KC and G-CSF may 
exert direct effects on islet function. 
Both factors were initially tested at 1-
100 ng/mL, with maximal effects seen 
at 100 ng/mL. When added at 100 
ng/ml for 4 days, both factors had a 
mild effect on β-cell apoptosis [control: 
0.33 ± 0.11; 100 ng/ml KC: 0.85 ± 
0.35; 100 ng/ml G-CSF: 0.41 ± 0.03 
TUNEL β-cells/islet (p>0.05, n=5), 
with a minimal effect on glucose-
stimulated insulin secretion (control: 
2.9 ± 0.2 fold; 100 ng/ml KC: 2.3 ± 0.3 
fold insulin secretion (p<0.05, n=4)]. 
Thus, we hypothesized that these 
factors were more important in 
mediating indirect effects on islets 
rather than having direct effects on β-
cells themselves.  
 To evaluate whether in vitro 
regulation of cytokine/chemokine 
release by a diabetic milieu could be 
relevant in vivo, C57BL/6J mice were 
subjected to HF diet feeding in order 
to investigate the islets ex vivo. After 4 
weeks on HF diet there was no 
increase in ex vivo islet 
cytokine/chemokine release despite a 
slight impairment in islet function as 
assessed by glucose-stimulated 
insulin secretion (not shown). 
However, after 8 weeks of HF feeding 
there was both an impairment in islet 
function, and a doubling of the same 
cytokines/chemokines regulated by a 
diabetic milieu in vitro (IL-6, 
chemokine KC, and G-CSF) 
compared to control islets (Figure 6). 
Finally, circulating serum KC was 
significantly elevated in 8 week HF fed 
animals versus controls (Figure 6B, 
p<0.05, n=4). The present study and 
independent experiments in our 
laboratory have found no increase in 
islet area by 8 weeks of high fat 
feeding (data not shown; n=5), 
indicating that these effects are not 
secondary to an increase in islet 
mass.   
 
IL-8 co-localizes to human α-cells, 
and mediates the migration of 
monocytes and neutrophils 
towards isolated islets exposed to 
a type 2 diabetic milieu.  Given 
those factors induced by a type 2 
diabetic milieu in human islets, we 
hypothesized that the chemokine IL-8 
may be responsible for the migration 
of monocytes towards islets in type 2 
diabetes. IL-8 is known to attract both 
monocytes and neutrophils, and it was 
most strongly induced by 
glucolipotoxicty in human islets 
(Figure 3D). Initially, we analyzed the 
localization of IL-8 in the human 
pancreas and in human isolated islets. 
We found IL-8 expression in human 
islets to be localized to glucagon-
positive endocrine cells, suggesting 
that islet IL-8 is mainly α-cell-derived 
(Figure 7A; 1-15). Indeed, by EM on 
ultrathin serial sections of isolated 
human islets, IL-8 was co-localized to 
glucagon-positive α-cell granules 
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(Figure 7B) and not found in β-cells or 
δ-cells (not shown). The specificity of 
the antibody used for immunostaining 
was isotype controlled, tested by 
preabsorption with recombinant IL-8, 
tested on a positive control tissue 
(Figure 7A), and confirmed to bind the 
8 kD IL-8 protein in isolated human 
islets by Western blot (Figure 7C).  
 Next, we tested the hypothesis 
that those factors released by 
pancreatic islets exposed to a type 2 
diabetic milieu may recruit leukocytes. 
Flow cytometry analysis of migrated 
leukocytes revealed that conditioned 
medium taken from human islets had 
no effect on T-cell, B-cell, and NK cell 
migration (data not shown). However, 
monocyte and neutrophil migration 
was clearly increased by conditioned 
medium taken from diabetic milieu 
treated human islets (from islets 
treated with 33 mM glucose and 0.5 
mM pamitate; “treated”) compared to 
conditioned medium from untreated 
human islets (“untreated”; Figure 7D). 
Intriguingly, IL-8 neutralization 
completely reversed the increased 
monocyte and neutrophil migration 
induced by treatment of human islets 
with a diabetic milieu (Figure 7D). 
When taken together with the human 
and mouse islet in vitro and ex vivo 
data, this supports the concept that IL-
8 (or possibly chemokine KC in the 
rodent) may contribute to the immune 
cell infiltration we have observed in 
type 2 diabetes.    
 
DISCUSSION 
 
To the best of our knowledge, 
macrophage infiltration of pancreatic 
islets has not been systematically 
investigated in type 2 diabetes. Our 
data support the conclusion that 
increased numbers of immune cells, 
specifically macrophages, are 
associated with pancreatic islets in 
type 2 diabetes. Further, increased 
numbers of immune cells were 
associated with islets of type 2 
diabetes models, including the high fat 
fed C57BL/6J mouse, the GK rat, and 
the diabetic db/db mouse. Given the 
accumulation of immune cells around 
and within type 2 diabetic islets and 
our in vitro data highlighting the 
specificity of this response to 
endocrine cells, it is probable that this 
inflammatory process is directed 
towards the endocrine pancreas. This 
is keeping in mind that in obese 
patients other organs may display 
typical inflammatory characteristics; 
e.g. macrophages in adipose tissue 
(2; 3) and in atherosclerotic plaques 
(25).   
 Whether the presence of 
macrophages is causative to type 2 
diabetes islet pathology requires 
further investigation. Hess and 
colleagues have shown that bone 
marrow cells home to damaged β-
cells in a peri-islet fashion to promote 
islet regeneration (26). Possibly, early 
infiltration of macrophages may be 
beneficial to islet function and 
plasticity. However, as the disease 
progresses macrophages may play a 
role in accelerating pancreatic islet-
cell dysfunction and death. The 
presence of macrophages may also 
occur post-β-cell demise, acting to 
phagocytose dead islet tissue. To this 
end, we did not detect apoptotic cells 
in the vicinity of infiltrating immune 
cells.  
To further explore the 
molecular signals underlying 
increased numbers of macrophages 
associated with type 2 diabetic islets 
 12
© 
we investigated the release of 
cytokines and chemokines from both 
human and mouse islets exposed to a 
type 2 diabetic milieu and ex vivo from 
HF fed animals. In all cases we saw a 
pronounced increase in IL-6, IL-8, 
chemokine KC (rodent islets only), G-
CSF, and MIP-1α (human islets only) 
release due to a type 2 diabetic milieu. 
Further, in mouse islets, the increased 
release of KC and G-CSF could be 
blunted by treatment of islets with IL-
1Ra, the endogenous receptor 
antagonist of IL-1β (n=10, p<0.05, J.A. 
Ehses and M.Y. Donath, unpublished 
data). This suggests that β-cell 
production of IL-1β in diabetic islets 
(27; 28) may be a key regulator of the 
increased chemokine production. 
Furthermore, IL-1β, or other effector 
mechanisms, may be at the origin of 
the observed increased rate of β-cell 
apoptosis, since the macrophages 
were not associated with apoptotic 
cells. Therefore, antagonism of IL-1 in 
patients with type 2 diabetes may 
protect the islets not only from the 
direct toxic effects of IL-1β but also 
from the consecutive inflammatory 
process (29).  
While further investigation is 
required to test the true cellular origin 
of islet derived chemokines both in 
vitro and in vivo, our data suggest 
they are pancreatic islet cell-
derived. This may include an 
endocrine, endothelial, neuronal, 
and/or resident macrophage (or other 
immune cells) origin. However, in 
contrast to IL-8, G-CSF and MIP-1α, 
nutrient regulation of IL-6 seems not 
to occur at the mRNA level in islets, 
and its production level is similar in 
islets and non-islet pancreatic tissue. 
Our data is supported by a preliminary 
report that elevated palmitate can 
upregulate chemokine KC mRNA in 
addition to other chemokines (MCP-1, 
SDF-1) in MIN-6 β-cells (30). In 
addition, transcripts for chemokines in 
isolated β-cells and β-cell lines have 
been shown to be induced by 
cytokines mimicking the type 1 
diabetic milieu (IL-1β, TNFα, IFNγ) 
(31-34). Chemokine KC was also 
strongly induced in these studies (33; 
34). Comparing these studies with our 
data shows that both the pattern of 
islet chemokines induced by 
glucose/palmitate versus IL-1β (or a 
cytokine cocktail) as well as the 
magnitude of effect, may be different. 
However, these differences may 
simply be due to concentration-
dependent effects of IL-1β.  
 Increased migration of both 
monocytes and neutrophils was 
induced by conditioned medium from 
islets exposed to a type 2 diabetic 
milieu, and was completely reversed 
by IL-8 neutralization. Thus, IL-8 
presents itself as an intriguing 
candidate contributing to inflammation 
in type 2 diabetic islets. Circulating IL-
8 has been shown to be elevated in 
type 2 diabetics (10; 11), and IL-8 
expression is elevated in the adipose 
tissue of obese insulin resistance 
subjects (35). Further, hyperglycemia 
has been shown to increase aortic 
endothelial cell IL-8 secretion and 
thereby promote monocyte adhesion 
(13). Our levels of IL-8 release are 
very similar to those needed for 
monocyte adhesion to endothelia (12; 
13). Given that circulating IL-8 levels 
are very low, it is possible that islet 
produced IL-8 may promote a 
concentration gradient leading to 
monocyte transmigration and 
infiltration.  
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 In conclusion, we have 
detected the presence of increased 
numbers of macrophages in 
pancreatic islets from patients with 
type 2 diabetes. In fact, in HF fed mice 
and GK rats increased islet 
macrophages were detected early 
during disease progression. 
Furthermore, elevated glucose and 
palmitate concentrations increased 
chemokine release from human and 
mouse pancreatic islets both in vitro 
and ex vivo. In particular, we localized 
IL-8 to the human α-cell and 
demonstrated the ability of a type 2 
diabetic milieu to enhance immune 
cell chemotaxis, an effect regulated by 
islet-derived IL-8.  
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Table 1:  Source of tissue samples used for analysis of CD68, CD163, CD3, 
and HLA-2 in diabetic and non-diabetic individuals.  All tissue samples were 
obtained from the Department of Pathology, University Hospital of Zurich, 
Switzerland. Patients with pancreatitis, lymphoma, systemic infection, and on 
immunosuppressive therapy were excluded from analysis. 
 
 
 
Patient 
no. 
Age 
(yrs) 
Sex 
(M/F) 
BMI 
(kg/m2) 
FPG 
(mM) 
Source of 
pancreas 
 
Reason Diabetes 
therapy 
Nondiabetic 1 51 M 21 4.7 Operation Carcinoma N/A 
 2 63 F N/A 4 Operation 
Benign endocrine 
pancreas tumor N/A 
 3 63 M 23 4.4 Operation Carcinoma N/A 
 4 89 F 25 3.6 Necropsy Aorta dissection N/A 
 5 81 F 25 5.3 Necropsy 
Ischemic heart 
disease N/A 
 6 74 F 24 5.7 Necropsy Cardiac shock N/A 
 7 72 M 21 4.5 Necropsy 
Ischemic heart 
disease N/A 
Mean  70  23.2 4.6    
Diabetic 8 64 M 26 11.7 Operation Carcinoma Diet 
 9 66 F 29 7.3 Operation 
Benign endocrine 
pancreas tumor Insulin 
 10 63 F 33 15 Operation Carcinoma Diet 
 11 68 M 32 10.7 Operation 
Ectopic spleen, 
normal pancreas Diet 
 12 61 M N/A 16 Organ Donor Transplantation N/A 
 13 83 F 23 9.8 Necropsy 
Ischemic heart 
disease Diet 
 14 77 M 26 8.4 Necropsy 
Ventricular 
fibrillation 
Oral antidiabetic 
(metformin) 
 15 56 F 22 25 Necropsy 
Ischemic heart 
disease Diet 
 16 74 F 23 14.7 Necropsy 
Ischemic heart 
disease 
Oral antidiabetic 
(metformin) 
Mean  68  26.8 * 13.2 *    
* p<0.05 vs nondiabetic patients. N/A = not available/not applicable 
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FIGURE LEGENDS 
 
Figure 1.  Increased number of islet macrophages in type 2 diabetic islets.  
Increased islet associated macrophages in human type 2 diabetic islets (A-B) 
and the high fat fed C57BL/6J mouse (C-E). In (A-B), islet-associated 
macrophages were detected by insulin (red) and CD68 (brown, arrows) staining 
of organ samples (see Table 1 for tissue sources). A representative control islet 
(B, 1), an islet from a type 2 diabetic patient (B, 2), and an isotype control stained 
islet (B, 3) are shown. In serial sections, TUNEL+ cells were evaluated in CD68+ 
infiltrated human islets and a representative islet from a type 2 diabetic patient 
stained for CD68 (B, 4) and TUNEL (B, 5) is shown. The CD68+ region outlined 
in (B, 4) is enlarged in (B, 6). All images are 200X, except (B, 6) which is shown 
at 400X. Islet associated Cd11b+ cells (C) were increased around large islets in 
8 and 16 week HF fed C57BL/6J animals versus equal-sized normal chow 
control islets (n=3-7). IPGTTs are shown for each group of animals (C). In (D-E), 
islet-associated Cd11b+ cells (7 and 8) and antibody specificity (9 and 10) are 
shown in C57BL/6J mice (8 week chow and HF fed). All images are 200X. Where 
* represents p<0.05 as determined using Student’s t-test.   
 
Figure 2.  Increased number of islet macrophages in the GK rat. Increased 
islet associated macrophages were detected in the 2-month old GK rat. 
Macrophages were stained using anti-CD68 (brown; E) and anti-MHC class 2 
antibodies with H & E counterstaining. Numbers of islet associated CD68 (A) and 
MHC-2 cells (C) were scored in 6 to 9 different animals. The mean islet area was 
identical in both strains for these comparisons (B and D). Representative images 
of a control Wistar islet (E, 1) and a GK islet (E, 2) stained for CD68 (arrows) are 
shown. Where * represents p<0.05 as determined using Student’s t-test.    
 
Figure 3.  Elevated glucose and palmitate increase cytokine/chemokine 
release from mouse and human islets.  It was confirmed that 48 h treatment 
with 33 mM glucose (33 mM) and 0.5 mM palmitate (16:0; alone or in 
combination) were detrimental to mouse and human islet function (A, B). Islet 
function (A) was assessed by acute (1 h) glucose stimulated insulin secretion 
(mouse n=3-6; human n=7). Simultaneously, after 48 h of treatment with 33 mM 
glucose and 0.5 mM palmitate (alone or in combination) cytokines/chemokines 
were assayed (C-H) from mouse and human islet conditioned medium 
representing 20 islets/dish. Basal concentrations of cytokines/chemokines for 
human islet experiments are provided on respective graphs. All experiments 
were conducted in triplicate (mouse n=3-6; human n=7), where * represents 
p<0.05 as tested by Student’s t-test, or ANOVA with Dunnett’s post hoc test. 
 
Figure 4.  Specificity of the inflammatory response to elevated glucose and 
palmitate in islets, non-endocrine tissue, and β-cell lines.  Mouse pancreatic 
islets and non-endocrine pancreatic tissue were plated on ECM dishes and 
treated for 48 h with 33 mM glucose and 0.5 mM palmitate (33/16:0). Conditioned 
medium was assayed for IL-6 (A), chemokine KC (B), G-CSF (C), and IP-10 (D) 
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and corrected for total protein. MIN-6 cells and INS-1 cells were plated in 24-well 
plates and treated for 48 h with 33 mM glucose (33 mM) and 0.5 mM palmitate 
(16:0; alone or in combination). Conditioned medium was assayed for chemokine 
KC (E, F), G-CSF (G), and MIP-1α (H) and corrected for total protein. Mouse 
pancreatic islets were treated for 48 h with 0.1 and 1 mM streptozotocin (I), or 
500 nM staurosporine (J). Conditioned medium was assayed for detection of IL-
6, chemokine KC, and G-CSF. Streptozotocin (1 mM) and staurosporine (500 
nM) were confirmed to induce cell death by TUNEL staining (K). Conditioned 
medium was always collected at the end of the 48 h treatment period. All 
experiments were conducted in triplicate (A-D: n=4; E: n=2; F-H: n=5; I-K: n=3), 
where * and # represent p<0.05 as determined using ANOVA with Bonferonni’s 
post hoc test. 
 
Figure 5.  Elevated glucose and palmitate increase chemokine KC, G-CSF, 
and MIP-1α mRNA in mouse islets.  Mouse islets were isolated and treated 
with 33 mM glucose (33 mM) and 0.5 mM palmitate (16:0; alone or in 
combination) for 48 h. Total islet RNA was extracted and reverse transcribed 
using random hexamers. Primers were used to detect IL-6 (A), chemokine KC 
(B), G-CSF (C), and MIP-1α (D) mRNA.  Cytokine/chemokine mRNA vs. an 18S 
control was assayed using the Taqman® quantitative PCR system and data are 
shown as fold of control. Where * represents p<0.05 as tested by ANOVA and 
Dunnett’s post hoc test  (n=3-4). 
 
Figure 6.  High fat diet increases IL-6, chemokine KC, and G-CSF release 
from isolated islets.  Mouse islets were isolated from animals fed normal chow 
or a high fat diet for 8 weeks. In (A) twenty islets/dish were plated and after 48 h 
assessed for islet function; HF fed animal islets showed impaired acute glucose 
stimulated insulin secretion vs. controls. Serum KC (B) was significantly elevated 
in HF fed animals after 8 weeks. Conditioned medium was assayed for IL-6 (C), 
chemokine KC (D), G-CSF (E), and IP-10 (F).  Experiments were performed in 
triplicate on 5 animals (n=5), where * represents p<0.05 as determined using 
Student’s t-test. 
    
Figure 7.  IL-8 co-localizes to human α-cells, and mediates the migration of 
monocytes and neutrophils induced by conditioned medium from human 
islets.  IL-8 expression was detected in human pancreatic resection samples (A: 
2, 5, 8, 11; representative of 3-7 different patient samples), isolated human non-β 
cells (A:14), and isolated human islets (B,C). Antibody specificity was tested by 
preabsorption with recombinant IL-8 (A:1-3), by isotype controls (A: 1, 5), and 
using brain glioblastoma as a positive control (A, 4). IL-8 staining did not co-
localize with insulin positive β-cells within the pancreatic islet, and did co-localize 
with glucagon positive α-cells (A, 7-9; 10-12; and 13-15). Electron microscopic 
investigation of IL-8 and glucagon visualised with double immunogold labelling 
(B). Large image shows overview of a glucagon cell. N: Nucleus. Square 
designates region shown at higher magnification (insert). Small image reveals 
that some granules contain IL-8 (15 nm gold particles) and glucagon (5 nm gold 
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particles) immunoreactivities, whereas some are only immunoreactive for 
glucagon. Western blotting confirmed production of IL-8 by human islets. Shown 
are representative blots from two separate human islet samples, along with 
recombinant IL-8 as a control; the 8 kD band corresponds to IL-8 (C). 
Conditioned medium from the above experiment (Figure 3) was used in migration 
experiments with isolated human PMBCs and granulocytes (D). Human islet 
media was used as control; “untreated” refers to conditioned medium from 
untreated human islets, “treated” refers to conditioned medium from human islets 
treated with 33 mM glucose and 0.5 mM palmitate for 48 h. The effect of IL-8 
neutralization on CD14 high expressing monocyte and CD15 high expressing 
neutrophil migration is shown (n=5 and n=2 respectively). Isotype IgG antibody 
was added to all conditions not including IL-8 Ab (“-“). Experiments were 
performed in triplicate, where * and # represent p<0.05 as determined using 
represent p<0.05 as determined using ANOVA with Bonferonni’s post hoc test.     
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Figure 4I-K 
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Figure 5 
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